Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $288.00. The company’s shares closed yesterday at ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

In a report released today, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of $305.00. The company’s share ...

Made by Amgen, MariTide was among several next-generation treatments for diabetes and obesity discussed at a meeting of the American Diabetes Association in Chicago, which concluded Monday.